Mohammed El-Kurdi, PhD, brings to Xeltis over 20 years of experience in cardiovascular bioengineering. He specializes in understanding and controlling the interaction between biomaterial-based medical devices and the diseased cardiovascular system.
His scientific work is dedicated to translating the potential of regenerative medicine technologies into clinically viable solutions, in order to deliver next-generation treatment alternatives to clinicians and their patients.
Prior to Xeltis, El-Kurdi co-founded the medical device startup Neograft, which was spun-off from technology invented through his doctoral research at the University of Pittsburgh. He is an inventor on 25 issued US patents, 4 “Notices of Allowance”, and 29 pending patent applications worldwide. He has authored 11 peer reviewed journal articles, and is active in the scientific community through his association with the International Society for Applied Cardiovascular Biology (ISACB), the Biomedical Engineering Society (BMES), the American Society for Mechanical Engineers (ASME), and the American Society for Artificial Internal Organs (ASAIO).